Accelerating knowledge turns: the I-SPY model and drug development
I-SPY Principal Investigator Laura Esserman's lecture at 'Rejuvenation Biology 2014' discussing how we can accelerate the pace of new drug development in oncology, including the role for adaptive platform trials.
Length: 31:37 min
Reinventing clinical trials
Laura Esserman's 2015 lecture at 'Exponential Medicine' discussed the re-engineering of clinical trials, inspired by the insights of late Intel CEO Andy Grove into the differences between development in the semiconductor industry and healthcare.
Length: 26:50 min
I-SPY 2 and other platform trials
I-SPY2 Principal Statistician Don Berry of Berry Consultants explains the history and fundamentals of platform trial models and how they are changing drug development in breast cancer and beyond.
Length: 31:52 min
I-SPY Clinical Trials: And interview with Dr. Laura Esserman
Dr. Laura Esserman, director of the Carol Franc Buck Breast Care Center at University of California San Francisco, sits down with Rebecca Knight from MIT Lab for Financial Engineering to discuss the innovative I-SPY breast cancer clinical trials.
Length: 38:18 min
Changing strategies in the 'war on cancer'
Dr. Angela DiMichele, Professor of Medicine and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania and I-SPY 2 Site Operations Working Group Chair discusses the innovations of I-SPY 2 and testing of new antibody-drug conjugates.
Length: 34:32 min
How to design an adaptive trial - Lessons learned, so far
How do you design an adaptive trial? Scott Berry one of the adaptive trial experts at Berry Consultants presents a recipe for designing a high-impact adaptive trial, secret sauce included.
Length: 38:18 min
The I-SPY Trials
Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.